PURPOSE: Iron is essential for oxygen transport and oxidative metabolism; however, elevated iron stores can trigger overproduction of reactive oxygen species and induce DNA damage. Little is known about the association between body iron stores and glioma risk. This study examined the associations of iron levels measured in toenails and genetic variants linked to body iron stores with risk of glioma in a clinic-based case-control study. METHODS: Samples were collected a median of 24 days following glioma diagnosis in the cases (10th-90th percentile, range: 10-44 days). Nail iron levels were measured in 300 cases and 300 controls using neutron activation analysis. A total of 24 genetic variants associated with iron status were genotyped in 622 cases and 628 controls. Logistic regression was used to estimate odds ratios (OR) and 95 % confidence intervals (CI) for glioma risk according to toenail iron and the examined genotypes. RESULTS: No association was observed between toenail iron and glioma risk when restricting to cases with nails collected within ~3 weeks of diagnosis (OR = 0.93; 95 % CI 0.46, 1.87 comparing those with high (≥14 μg/g) vs. low (<6 μg/g) iron levels). In contrast, an inverse association with increasing iron was observed after restricting to cases with a delay of 3 weeks or greater (OR = 0.42; 95 % CI 0.19, 0.95), reflecting potentially insidious effects of advancing disease on iron levels among the cases. No associations were observed for any of the examined genetic variants. CONCLUSION: The results do not support a role for body iron stores as a determinant of glioma risk.
PURPOSE:Iron is essential for oxygen transport and oxidative metabolism; however, elevated iron stores can trigger overproduction of reactive oxygen species and induce DNA damage. Little is known about the association between body iron stores and glioma risk. This study examined the associations of iron levels measured in toenails and genetic variants linked to body iron stores with risk of glioma in a clinic-based case-control study. METHODS: Samples were collected a median of 24 days following glioma diagnosis in the cases (10th-90th percentile, range: 10-44 days). Nail iron levels were measured in 300 cases and 300 controls using neutron activation analysis. A total of 24 genetic variants associated with iron status were genotyped in 622 cases and 628 controls. Logistic regression was used to estimate odds ratios (OR) and 95 % confidence intervals (CI) for glioma risk according to toenail iron and the examined genotypes. RESULTS: No association was observed between toenail iron and glioma risk when restricting to cases with nails collected within ~3 weeks of diagnosis (OR = 0.93; 95 % CI 0.46, 1.87 comparing those with high (≥14 μg/g) vs. low (<6 μg/g) iron levels). In contrast, an inverse association with increasing iron was observed after restricting to cases with a delay of 3 weeks or greater (OR = 0.42; 95 % CI 0.19, 0.95), reflecting potentially insidious effects of advancing disease on iron levels among the cases. No associations were observed for any of the examined genetic variants. CONCLUSION: The results do not support a role for body iron stores as a determinant of glioma risk.
Authors: Zoltán Kutalik; Beben Benyamin; Sven Bergmann; Vincent Mooser; Gérard Waeber; Grant W Montgomery; Nicholas G Martin; Pamela A F Madden; Andrew C Heath; Jacques S Beckmann; Peter Vollenweider; Pedro Marques-Vidal; John B Whitfield Journal: Hum Mol Genet Date: 2011-06-10 Impact factor: 6.150
Authors: Amanda J Cross; Marc J Gunter; Richard J Wood; Pirjo Pietinen; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes; Rashmi Sinha Journal: Int J Cancer Date: 2006-06-15 Impact factor: 7.396
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: Jordan H Creed; Noah C Peeri; Gabriella M Anic; Reid C Thompson; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; John D Brockman; Travis A Gerke; Louis B Nabors; Kathleen M Egan Journal: Sci Rep Date: 2019-07-26 Impact factor: 4.379
Authors: Antoni Sureda; Maria Del Mar Bibiloni; Alicia Julibert; Raquel Aparicio-Ugarriza; Gonzalo Palacios-Le Blé; Antoni Pons; Marcela Gonzalez-Gross; Josep A Tur Journal: PLoS One Date: 2017-10-06 Impact factor: 3.240
Authors: Noah C Peeri; Jordan H Creed; Gabriella M Anic; Reid C Thompson; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; John D Brockman; Travis A Gerke; L Burton Nabors; Kathleen M Egan Journal: Cancer Epidemiol Date: 2018-05-25 Impact factor: 2.984